Wall Street analysts predict that Bruker Co. (NASDAQ:BRKR) will report $454.83 million in sales for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Bruker’s earnings, with the highest sales estimate coming in at $462.36 million and the lowest estimate coming in at $448.64 million. Bruker posted sales of $431.70 million during the same quarter last year, which would indicate a positive year over year growth rate of 5.4%. The business is expected to announce its next quarterly earnings results on Thursday, May 2nd.

On average, analysts expect that Bruker will report full-year sales of $2.02 billion for the current fiscal year. For the next fiscal year, analysts expect that the firm will report sales of $2.11 billion, with estimates ranging from $2.10 billion to $2.13 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that follow Bruker.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Monday, February 11th. The medical research company reported $0.54 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.54. Bruker had a return on equity of 26.36% and a net margin of 9.48%. The firm had revenue of $553.60 million for the quarter, compared to analysts’ expectations of $544.53 million.

Several analysts have issued reports on BRKR shares. Zacks Investment Research cut Bruker from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 7th. BTIG Research restated a “buy” rating and set a $44.00 price objective (up previously from $42.00) on shares of Bruker in a research note on Tuesday, February 12th. Needham & Company LLC assumed coverage on Bruker in a research note on Wednesday, January 2nd. They set a “strong-buy” rating and a $39.00 price objective on the stock. BidaskClub raised Bruker from a “hold” rating to a “buy” rating in a report on Friday, January 11th. Finally, Deutsche Bank raised Bruker from a “hold” rating to a “buy” rating and upped their target price for the company from $40.00 to $50.00 in a report on Friday. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $38.14.

Large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. grew its holdings in shares of Bruker by 33.4% during the third quarter. JPMorgan Chase & Co. now owns 96,033 shares of the medical research company’s stock valued at $3,213,000 after purchasing an additional 24,048 shares during the last quarter. Man Group plc grew its holdings in shares of Bruker by 120.0% during the third quarter. Man Group plc now owns 461,627 shares of the medical research company’s stock valued at $15,442,000 after purchasing an additional 251,764 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Bruker by 4.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,013,763 shares of the medical research company’s stock worth $30,178,000 after buying an additional 46,244 shares in the last quarter. State Board of Administration of Florida Retirement System grew its holdings in Bruker by 0.4% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 144,802 shares of the medical research company’s stock worth $4,311,000 after buying an additional 510 shares in the last quarter. Finally, Rhumbline Advisers grew its holdings in Bruker by 3.3% in the 4th quarter. Rhumbline Advisers now owns 102,048 shares of the medical research company’s stock worth $3,038,000 after buying an additional 3,254 shares in the last quarter. 69.02% of the stock is owned by institutional investors.

Shares of NASDAQ BRKR opened at $39.59 on Friday. Bruker has a 52-week low of $26.10 and a 52-week high of $40.25. The company has a market cap of $6.13 billion, a price-to-earnings ratio of 28.28, a PEG ratio of 2.15 and a beta of 1.47. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.33 and a current ratio of 2.18.

The business also recently announced a quarterly dividend, which was paid on Friday, March 22nd. Stockholders of record on Tuesday, March 5th were issued a dividend of $0.04 per share. This represents a $0.16 annualized dividend and a dividend yield of 0.40%. The ex-dividend date of this dividend was Monday, March 4th. Bruker’s dividend payout ratio (DPR) is presently 11.43%.

About Bruker

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Read More: Stock Symbols and CUSIP Explained

Get a free copy of the Zacks research report on Bruker (BRKR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.